licensing

News

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts

News

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the

News

Takeda joins PIKfyve ALS push with AcuraStem deal

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar

News

Roche buys into Alnylam's twice-yearly blood pressure drug

Roche has paid $310 million upfront for rights to Alnylam Pharma's zilebesiran for hypertension, a handsome sum for a drug that so far has only generated phase 1 data.

News

Haleon nabs rights to Futura’s OTC erectile dysfunction gel

Just over a month after getting FDA approval for the first over-the-counter (OTC) topical therapy for erectile dysfunction (ED), Futura Medical has lined up some heavyweig

News

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

Takeda joins PIKfyve ALS push with AcuraStem deal

Roche buys into Alnylam's twice-yearly blood pressure drug

Haleon nabs rights to Futura’s OTC erectile dysfunction gel

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

licensing

Editor's Picks